Biopharmaceutical stocks require time and patience. But when the company does well, investors get rewarded like they have with Kiniksa Pharmaceuticals NASDAQ: KNSA. The stock is up more than 100% in the past year. Much of that growth came after the company's strong Q1 report on April 28, in which it increased adjusted earnings per share (EPS) estimates by 9 cents, coming in at 27 cents.
Kiniksa Pharmaceuticals International Today
Kiniksa Pharmaceuticals International
As of 05/22/2026 04:00 PM Eastern
- 52 week interval
- $25.70
▼
$59.87
- The P/E ratio
- 59.16
- Target Value
- $60.86
At that time, the company announced the launch of a TV campaign aimed directly at the consumer for ARCALYST in chronic pericarditis. ARCALYST is the first and only US Food & Drug Administration (FDA) approved treatment for recurrent pericarditis. It received this position in 2021.
After some initial volatility, ARCALYST saw revenue of $48 million in March 2023. Revenue growth accelerated, reaching a new record of $214.27 million in Q1 2026, a 56% year-over-year (YOY) gain. The new campaign is important because it shows that Kiniksa is investing in generating demand at scale rather than relying solely on drug growth.
To that end, the company raised its full-year revenue guidance to $930 million to $945 million. Previous guidance was in the range of $900 million to $920 million.
Single Focus Goes To Its Second Generation
Like many biotech companies, Kiniska is focused on discovering and developing novel, transformative therapies for patients with unmet medical needs. This company specializes in heart diseases, especially pericarditis.
Pericarditis is an inflammation of the pericardium—a small fluid-filled sac that surrounds the heart—causing severe chest pain, fatigue, and in severe cases, dangerous fluid around the heart. When the condition keeps coming back despite standard anti-inflammatory treatments like NSAIDs and colchicine, it becomes recurrent pericarditis, a chronic inflammatory disease driven by an overactive IL-1 immune response.
How big is this market? Approximately 40,000 patients in the US seek and receive treatment for recurrent pericarditis each year, approximately 14,000 of those with two or more recurrences due to persistent disease or inadequate response to standard therapies.
That 14,000 is roughly in line with Kiniksa's original target, of which 18% will be in ARCALYST by the end of 2025. That leaves about 80% of the repairable market neglected, and, for now, Kiniska has the platform to itself, and is working at full speed to keep competitors out.
That leads to the company's pipeline, which includes its drug KPL-387. This is a once-monthly subcutaneous injection that marks a significant improvement over the more common dose of ARCALYST. KPL-387, which is in a Phase 2 trial, received FDA Orphan Drug Designation (ODD) in October 2025.
Among the many benefits of ODD is that Kiniksa will have exclusive marketing rights for seven years. Investors in the biotech space as a specialty, and this is another opportunity for Kiniksa to deliver.
Measurement Can Be A Concern
Biotechnology stocks can be volatile, and Kiniksa is no exception. However, unlike many speculative biotech names that are not profitable and have little capital, Kiniksa has become a profitable company with profits growing sequentially and YOY.
That said, KNSA now trades at around 60x earnings. That's a significant premium to the S&P 500 (about 27x) and the broader biotech sector (about 17x). The case is that Kiniksa has earned this premium from the perspective of strong revenue growth and high margins.
Skeptics may argue that the current stock price depends on flawless performance, which may or may not happen. However, playing the wait-and-see game has not worked out well for investors sitting on the sidelines, and the consensus price target of $60.86 still leaves a healthy upside from current levels.
The KNSA Chart Makes an Argument to Wait
The technical picture supports a moderate approach for investors considering the position. After rising nearly 20% after the earnings report, KNSA retreated to the $53-$54 range on declining volume. This indicates a healthy strengthening, not a structural collapse. The relative strength index (RSI) has retreated from the overbought zone near 80 to the mid-51 zone, which means that the post-recovery momentum has been dealt with without much price damage. The MACD crossover, however, suggests that the modest selling pressure in the near term may not be completely eliminated.
Investors looking for a more defined entry point may want to look at the 50-day simple moving average, which is currently tracking in the $47-$49 range. A successful test of that level—especially if the MACD turns positive on a retest—will ensure the broader upside remains intact and provide a more risk-reward setup ahead of KPL-387 Phase 2 data expected in the second half of 2026.
Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.
MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Kiniksa Pharmaceuticals International was not on the list.
Although Kiniksa Pharmaceuticals International currently has a Neutral Buy rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
Looking for the next FAANG stock before everyone hears about it? Click the link to see which stocks MarketBeat analysts think could be the next billion dollar tech company.
Get This Free Report
